214 related articles for article (PubMed ID: 35413107)
1. Investigation of a Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) Variant Outbreak Among Residents of a Skilled Nursing Facility and Vaccine Effectiveness Analysis: Maricopa County, Arizona, June-July 2021.
Dale AP; Almendares O; Howard BJ; Burnett E; Prasai S; Arons M; Collins J; Duffy N; Pandit U; Brady S; White JR; Garrett B; Kirking HL; Sunenshine R; Tate JE; Scott SE
Clin Infect Dis; 2022 Aug; 75(1):e20-e26. PubMed ID: 35413107
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021.
Moline HL; Keaton A; Rice W; Varghese J; Deng L; Waters A; Barringer A; Winston D; Fields V; Slifka KJ; Verani JR; Schrag SJ; Jernigan J; Tate JE; Fleming-Dutra KE
Clin Infect Dis; 2022 Oct; 75(Suppl 2):S155-S158. PubMed ID: 35758873
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474
[TBL] [Abstract][Full Text] [Related]
5. Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunity.
Pierobon A; Zotto AD; Antico A; De Antoni ME; Vianello L; Gennari M; Di Caprio A; Russo F; Brambilla G; Saugo M
Clin Microbiol Infect; 2022 Apr; 28(4):614.e5-614.e7. PubMed ID: 34958917
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020-November 2021.
Hatfield KM; Baggs J; Wolford H; Fang M; Sattar AA; Montgomery KS; Jin S; Jernigan J; Pilishvili T
Clin Infect Dis; 2022 Oct; 75(Suppl 2):S147-S154. PubMed ID: 35856635
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS).
Maeda H; Saito N; Igarashi A; Ishida M; Suami K; Yagiuchi A; Kimura Y; Komino M; Arai H; Morikawa T; Motohashi I; Miyazawa R; Moriyama T; Kamura H; Terada M; Kuwamitsu O; Hayakawa T; Sando E; Ohara Y; Teshigahara O; Suzuki M; Morimoto K
Clin Infect Dis; 2022 Nov; 75(11):1971-1979. PubMed ID: 35438137
[TBL] [Abstract][Full Text] [Related]
8. Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021.
Lewis JW; Loughran J; Deng L; Varghese J; Clark S; Harrison C; Gacetta M; Jernigan JA; Fleming-Dutra KE
Emerg Infect Dis; 2022 Nov; 28(11):2338-2341. PubMed ID: 36170764
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021.
Britton A; Jacobs Slifka KM; Edens C; Nanduri SA; Bart SM; Shang N; Harizaj A; Armstrong J; Xu K; Ehrlich HY; Soda E; Derado G; Verani JR; Schrag SJ; Jernigan JA; Leung VH; Parikh S
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(11):396-401. PubMed ID: 33735160
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 Outbreaks in Nursing Homes Despite Full Vaccination with BNT162b2 of a Majority of Residents.
Lafuente-Lafuente C; Rainone A; Guérin O; Drunat O; Jeandel C; Hanon O; Belmin J;
Gerontology; 2022; 68(12):1384-1392. PubMed ID: 35313315
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign.
van Ewijk CE; Hazelhorst EI; Hahné SJM; Knol MJ
Vaccine; 2022 Nov; 40(46):6664-6669. PubMed ID: 36216647
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021.
Cavanaugh AM; Fortier S; Lewis P; Arora V; Johnson M; George K; Tobias J; Lunn S; Miller T; Thoroughman D; Spicer KB
MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(17):639-643. PubMed ID: 33914720
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
15. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.
Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB
Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020.
Kimball A; Hatfield KM; Arons M; James A; Taylor J; Spicer K; Bardossy AC; Oakley LP; Tanwar S; Chisty Z; Bell JM; Methner M; Harney J; Jacobs JR; Carlson CM; McLaughlin HP; Stone N; Clark S; Brostrom-Smith C; Page LC; Kay M; Lewis J; Russell D; Hiatt B; Gant J; Duchin JS; Clark TA; Honein MA; Reddy SC; Jernigan JA; ;
MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(13):377-381. PubMed ID: 32240128
[TBL] [Abstract][Full Text] [Related]
17. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.
Schrag SJ; Verani JR; Dixon BE; Page JM; Butterfield KA; Gaglani M; Vazquez-Benitez G; Zerbo O; Natarajan K; Ong TC; Lazariu V; Rao S; Beaver R; Ellington SR; Klein NP; Irving SA; Grannis SJ; Kiduko S; Barron MA; Midturi J; Dickerson M; Lewis N; Stockwell MS; Stenehjem E; Fadel WF; Link-Gelles R; Murthy K; Goddard K; Grisel N; Valvi NR; Fireman B; Arndorfer J; Konatham D; Ball S; Thompson MG; Naleway AL
JAMA Netw Open; 2022 Sep; 5(9):e2233273. PubMed ID: 36156146
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021.
Fabiani M; Puopolo M; Filia A; Sacco C; Mateo-Urdiales A; Spila Alegiani S; Del Manso M; D'Ancona F; Vescio F; Bressi M; Petrone D; Spuri M; Rota MC; Massari M; Da Cas R; Morciano C; Stefanelli P; Bella A; Tallon M; Proietti V; Siddu A; Battilomo S; Palamara AT; Popoli P; Brusaferro S; Rezza G; Riccardo F; Menniti Ippolito F; Pezzotti P
Expert Rev Vaccines; 2022 Jul; 21(7):975-982. PubMed ID: 35389748
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of prior third dose mRNA vaccination in rural nursing home residents during SARS-CoV-2 outbreaks.
Rhynold ES; Quan S; Orr PH; LaBine L; Singer A; St John PD
J Am Geriatr Soc; 2022 Nov; 70(11):3245-3249. PubMed ID: 35938635
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
